Greenwich Lifesciences Stock Performance
| GLSI Stock | USD 11.11 0.23 2.03% |
The company retains a Market Volatility (i.e., Beta) of 1.14, which attests to a somewhat significant risk relative to the market. Greenwich Lifesciences returns are very sensitive to returns on the market. As the market goes up or down, Greenwich Lifesciences is expected to follow. At this point, Greenwich Lifesciences has a negative expected return of -0.11%. Please make sure to check out Greenwich Lifesciences' treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Greenwich Lifesciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Greenwich Lifesciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest inconsistent performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders. ...more
Actual Historical Performance (%)
One Day Return (2.03) | Five Day Return (11.12) | Year To Date Return (5.37) | Ten Year Return 122.2 | All Time Return 122.2 |
1 | Acquisition by Mcwilliams David of 61984 shares of Greenwich Lifesciences at 12.16 subject to Rule 16b-3 | 12/24/2024 |
2 | Acquisition by Snehal Patel of 3200 shares of Greenwich Lifesciences at 11.12 subject to Rule 16b-3 | 12/30/2024 |
3 | Acquisition by Snehal Patel of 2400 shares of Greenwich Lifesciences at 11.36 subject to Rule 16b-3 | 12/31/2024 |
4 | Acquisition by Snehal Patel of 2500 shares of Greenwich Lifesciences at 12.51 subject to Rule 16b-3 | 01/10/2025 |
5 | Insider Buying Snehal Patel Acquires Additional Shares of Greenwich LifeSciences Inc | 01/13/2025 |
6 | Glancy Prongay Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. | 01/17/2025 |
7 | Greenwich LifeSciences Announces Additions of Harvard and Johns | 01/23/2025 |
8 | Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland | 01/27/2025 |
9 | Greenwich LifeSciences Approved to Add Additional Sites to FLAMI | 01/29/2025 |
10 | Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01 | 02/10/2025 |
11 | Greenwich LifeSciences Earns Buy Rating from HC Wainwright - MarketBeat | 02/14/2025 |
12 | Acquisition by Snehal Patel of 2000 shares of Greenwich Lifesciences at 9.72 subject to Rule 16b-3 | 02/25/2025 |
13 | Acquisition by Snehal Patel of 12000 shares of Greenwich Lifesciences at 8.33 subject to Rule 16b-3 | 03/06/2025 |
14 | Acquisition by Jaye Thompson of 149818 shares of Greenwich Lifesciences at 12.16 subject to Rule 16b-3 | 03/13/2025 |
15 | Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01 | 03/17/2025 |
| Begin Period Cash Flow | 13.5 M | |
| Free Cash Flow | -6.5 M |
Greenwich |
Greenwich Lifesciences Relative Risk vs. Return Landscape
If you would invest 1,216 in Greenwich Lifesciences on December 23, 2024 and sell it today you would lose (105.00) from holding Greenwich Lifesciences or give up 8.63% of portfolio value over 90 days. Greenwich Lifesciences is currently does not generate positive expected returns and assumes 2.9508% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than Greenwich, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Greenwich Lifesciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Greenwich Lifesciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Greenwich Lifesciences, and traders can use it to determine the average amount a Greenwich Lifesciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0357
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GLSI |
Estimated Market Risk
| 2.95 actual daily | 26 74% of assets are more volatile |
Expected Return
| -0.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Greenwich Lifesciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Greenwich Lifesciences by adding Greenwich Lifesciences to a well-diversified portfolio.
Greenwich Lifesciences Fundamentals Growth
Greenwich Stock prices reflect investors' perceptions of the future prospects and financial health of Greenwich Lifesciences, and Greenwich Lifesciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Greenwich Stock performance.
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.9 | ||||
| Current Valuation | 139.43 M | ||||
| Shares Outstanding | 13.14 M | ||||
| Price To Book | 29.15 X | ||||
| EBITDA | (9.32 M) | ||||
| Net Income | (8.89 M) | ||||
| Cash And Equivalents | 15.64 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 294.41 K | ||||
| Current Ratio | 65.74 X | ||||
| Book Value Per Share | 0.38 X | ||||
| Cash Flow From Operations | (6.48 M) | ||||
| Earnings Per Share | (0.81) X | ||||
| Market Capitalization | 146.04 M | ||||
| Total Asset | 6.99 M | ||||
| Retained Earnings | (50.36 M) | ||||
| Working Capital | 6.7 M | ||||
About Greenwich Lifesciences Performance
By evaluating Greenwich Lifesciences' fundamental ratios, stakeholders can gain valuable insights into Greenwich Lifesciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Greenwich Lifesciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Greenwich Lifesciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.14) | (1.20) | |
| Return On Capital Employed | (1.60) | (1.52) | |
| Return On Assets | (1.14) | (1.20) | |
| Return On Equity | (1.53) | (1.45) |
Things to note about Greenwich Lifesciences performance evaluation
Checking the ongoing alerts about Greenwich Lifesciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Greenwich Lifesciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Greenwich Lifesciences generated a negative expected return over the last 90 days | |
| Greenwich Lifesciences has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (8.89 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Greenwich Lifesciences currently holds about 15.64 M in cash with (6.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22. | |
| Greenwich Lifesciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 53.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01 |
- Analyzing Greenwich Lifesciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Greenwich Lifesciences' stock is overvalued or undervalued compared to its peers.
- Examining Greenwich Lifesciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Greenwich Lifesciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Greenwich Lifesciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Greenwich Lifesciences' stock. These opinions can provide insight into Greenwich Lifesciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Greenwich Stock analysis
When running Greenwich Lifesciences' price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |